Here are the 10-Q quarterly reports from Aktis Oncology, Inc. (AKTS) in our archive since June 2025, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 10-Q covers the quarterly report filed between annual reports, so if you follow AKTS and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full AKTS filings page.
Aktis Oncology, Inc. reported Q2 2026 as an early-stage, clinical oncology company investing heavily in its radiopharmaceutical pipeline. Collaboration revenue from its Eli Lilly agreement rose to $3.4 million for the quarter and $6.6 million year-to-date. Operating expenses expanded, with Q2 research and development at $25.3 million and general and administrative at $7.0 million, driving a quarterly net loss of $24.1 million and a six‑month loss of $42.5 million. Following a January 2026 IPO and conversion of preferred stock, the balance sheet strengthened: cash, cash equivalents, and marketable securities totaled $517.3 million, and stockholders’ equity reached $484.8 million as of June 30, 2026. Management believes this liquidity will fund operations into 2029, while it advances lead candidates [225Ac]Ac‑AKY‑1189 and [225Ac]Ac‑AKY‑2519 through clinical development.
Aktis Oncology reported its first quarterly results as a public company, showing higher collaboration revenue and a much stronger balance sheet after its IPO. Collaboration revenue from its Eli Lilly partnership grew to $3.2 million for the three months ended March 31, 2026, up from $1.4 million a year earlier. Operating expenses rose to $25.9 million, driven mainly by increased R&D spending on lead radiopharmaceutical candidates [225Ac]Ac-AKY-1189 and [225Ac]Ac-AKY-2519 and higher public-company G&A costs, resulting in a net loss of $18.3 million versus $15.0 million in 2025. The January 2026 IPO and preferred share conversion transformed the capital structure, leaving Aktis with $538.5 million in cash, cash equivalents and marketable securities and total stockholders’ equity of $506.1 million. Management believes this cash runway will fund operations into 2029 as the company advances its miniprotein radioconjugate platform and clinical programs.